5/20
07:17 am
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $23.00 price target on the stock.
Low
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $23.00 price target on the stock.
5/14
08:07 am
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $16.00 to $14.00. They now have an "outperform" rating on the stock.
Medium
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $16.00 to $14.00. They now have an "outperform" rating on the stock.
5/14
08:07 am
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Medium
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
5/14
08:04 am
fulc
Sanofi to make €1bn biomanufacturing investment in France [Yahoo! Finance]
Low
Report
Sanofi to make €1bn biomanufacturing investment in France [Yahoo! Finance]
5/14
07:08 am
fulc
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely? [Yahoo! Finance]
Low
Report
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely? [Yahoo! Finance]
5/13
04:39 pm
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $15.00 price target on the stock.
Low
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $15.00 price target on the stock.
5/13
07:12 am
fulc
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 [Yahoo! Finance]
5/13
07:00 am
fulc
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
Medium
Report
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
5/13
06:11 am
fulc
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy [Yahoo! Finance]
High
Report
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy [Yahoo! Finance]
5/13
06:00 am
fulc
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
High
Report
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
5/9
08:12 am
fulc
Fulcrum Therapeutics to Participate in Upcoming May Conferences [Yahoo! Finance]
Low
Report
Fulcrum Therapeutics to Participate in Upcoming May Conferences [Yahoo! Finance]
5/9
08:00 am
fulc
Fulcrum Therapeutics to Participate in Upcoming May Conferences
Low
Report
Fulcrum Therapeutics to Participate in Upcoming May Conferences
5/8
08:21 am
fulc
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology [Yahoo! Finance]
Low
Report
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology [Yahoo! Finance]
5/8
08:00 am
fulc
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
Low
Report
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
5/6
08:00 am
fulc
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
Medium
Report
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
3/28
04:05 pm
fulc
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
Low
Report
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
3/22
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/18
07:09 am
fulc
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
High
Report
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
3/18
07:00 am
fulc
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
High
Report
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
3/13
08:15 am
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $14.00 price target on the stock.
Low
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $14.00 price target on the stock.
3/8
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/7
06:57 am
fulc
CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock [Yahoo! Finance]
Low
Report
CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock [Yahoo! Finance]
3/6
12:17 pm
fulc
Fulcrum hits 52-week high as CEO buys shares [Seeking Alpha]
Medium
Report
Fulcrum hits 52-week high as CEO buys shares [Seeking Alpha]
3/5
08:00 am
fulc
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
Medium
Report
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference